Apexigen Presents New Data from a Phase 2 Trial Evaluating :

-Sotigalimab in combination with neoadjuvant chemoradiation induced higher pathologic complete response rates, an important predictor of survival, in...

Related Keywords

Paris , France General , France , Andrew Ko , Frank Hsu , Bruce Mackle , William Duke , Apexigen Inc , Securities Exchange , University Of California San Francisco , European Society For Medical Oncology , Nasdaq , European Society , Medical Oncology , Clinical Medicine , California San Francisco , Principal Investigator , Chief Medical Officer , Guillain Barre Syndrome , California San , Session Date , Securities Act , Securities Exchange Act , Nasdaq Apgn , Apexigen ,